Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Cancer Diagnosis & Prognosis|September 6, 2023
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on SurvivalElisabetta Gambale, Valeria Emma Palmieri, Virginia Rossi, et al.
Anti-Cancer Drugs|June 22, 2007
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapyRoberto Petrioli, Loretta Paolelli, Edoardo Francini, et al.
Anti-Cancer Drugs|November 29, 2007
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal TumorsRoberto Petrioli, Alessandra Pascucci, Edoardo Francini, et al.
Anti-Cancer Drugs|December 18, 2009
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatinRoberto Petrioli, Gianluca Bargagli, Stefano Lazzi, et al.
Oncology|December 21, 2006
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancerRoberto Petrioli, Loretta Paolelli, Stefania Marsili, et al.
Anti-Cancer Drugs|December 19, 2019
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancerRoberto Petrioli, Edoardo Francini, Sara Cherri, et al.
Prostate Cancer and Prostatic Diseases|January 16, 2019
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registryEdoardo Francini, Kathryn P Gray, Grace K Shaw, et al.
International Journal of Clinical Oncology|January 18, 2011
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancerFilippo Francini, Alessandra Pascucci, Gianluca Bargagli, et al.
Therapeutics and Clinical Risk Management|November 21, 2013
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot studyLuigi Rossi, Federica Tomao, Giuseppe Lo Russo, et al.
Surgical Oncology|November 1, 2019
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancerRoberto Petrioli, Daniele Marrelli, Franco Roviello, et al.
Pageof 8